Journals / Nöropsikiyatri Arşivi / 2021 / Cilt: 58 - Sayı: 4

Proteasome Modulator 9 Gene rs14259 Polymorphism in Patients with Diabetic Polyneuropathy

Diyabetik Polinöropati Hastalarında Proteazom Modülatör 9 Geni rs14259 Polimorfizmi

Pages
289–291
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The present findings show that the GG genotype and G allele of PSMD9 rs14259 polymorphism may be associated with an increased risk of DSPN in Turkish DM patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Diabetic polyneuropathy (DPN) is a major chronic neurological complication of diabetes mellitus (DM) and typically presents as diabetic sensory polyneuropathy (DSPN).
📊
Key Findings & Data:The proteasome modulator 9 gene (PSMD9) is a transcriptional regulator of the insulin gene and its variants cause beta-cell dysfunction that devastates insulin transcription.
💡
Conclusion & Impact:Conclusion: The present findings show that the GG genotype and G allele of PSMD9 rs14259 polymorphism may be associated with an increased risk of DSPN in Turkish DM patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Diabetic polyneuropathy (DPN) is a major chronic neurological complication of diabetes mellitus (DM) and typically presents as diabetic sensory polyneuropathy (DSPN). Whereas some patients with similar risk factors develop polyneuropathy, others don’t, which suggests that genetics plays an important role in the progression of disease. The proteasome modulator 9 gene (PSMD9) is a transcriptional regulator of the insulin gene and its variants cause beta-cell dysfunction that devastates insulin transcription. The aim of this study was to determine the correlation between PSMD9 rs14259 polymorphism and the risk of DSPN in Turkish DM patients with DPN. Methods: The study included 31 DM patients with DSPN and 29 healthy controls. All participants underwent electrophysiological investigation. In addition, DNA was isolated from peripheral blood samples for the genotyping of PSMD9 rs14259 polymorphism. Results: Mean age in the DSPN and control groups was 58.03±9.59 years and 57.62±12.32 years, respectively. There were significant differences between the DSPN and controls groups in the frequencies of the genotype for AA (n=9 and n=12, respectively), AG (n=10 and n=15, respectively), and GG (n=12 and n=2, respectively). According to the distribution of PSMD9 rs14259 polymorphism, 45.2% (n=28) of the patients and 67.2% (n=39) of the controls had the A allele, and 54.8% (n=34) of the patients and 32.8% (n=19) of the controls had the G allele, whereas the frequency of the G allele of rs14259 was significantly higher in the DSPN group (X2=1.059, P=0.015) than in the control group (OR: 2.49; 95% CI: 1.18–5.23). Conclusion: The present findings show that the GG genotype and G allele of PSMD9 rs14259 polymorphism may be associated with an increased risk of DSPN in Turkish DM patients.

Özet

Amaç: Diyabetik polinöropati (DPN), diyabetes mellitus (DM) hastalığının majör nörolojik komplikasyonudur ve tipik olarak diyabetik duysal polinöropati (DDPN) varyasyonu olarak görülür. Benzer risk faktörü olan hastaların bazıları polinöropati geliştirirken bazılarının geliştirmemesi hastalığın genetik altyapısının olduğunu düşündürmektedir. Proteazom modülatör 9 geni (PSMD9) rs14259 polimorfizmi, insülin geninin transkripsiyon regulatörüdür ve variantları beta hücrelerinin disfonksiyonuna yol açarak insulin transkripsiyonunu bozmaktadır. Bu çalışmanın amacı Türk DPN’li DM hastalarında, proteazom PSMD9 rs14259 polimorfizmi ile DDPN riski arasındaki korelasyonu araştırmaktır. Metod: Araştırmaya DDPN’si olan 31 DM hastası ve 29 sağlıklı birey alınmış olup tüm hastalar elekrofizyolojik araştırmaya dahil edilmiştir. Ayrıca bu hastaların periferik kan örneklerinden DNA izole edilip PSMD9 geni rs14259 genotiplenmiştir. Bulgular: Hastaların ve kontrollerin ortalama yaşı sırasıyla 58,03±9,59 ve 57,62±12,32 olarak saptanmıştır. Kontrol grubu ve DDPN hastaları arasındaki AA (n=9 ve n=12), AG (n=10 ve n=15) ve GG (n=12 ve n=2) genotip frekanslarının farklılıkları istatistiksel olarak anlamlı bulunmuştur. PSMD9 geni rs14259 polimorfizmi dağılımı A allelli DDPN hastalarda 45,2% (n=28), kontrollerde 67,2% (n=39) ve G alleli DDPN hastalarda 54,8% (n=34), kontrollerde 32,8% (n=19) saptanırken, rs14259’de G alellinin frekansı DDPN hastalarında anlamlı olarak daha yüksek olduğu bulunmuştur (X2=1,059; p=0,015; OR:2,49; %95 CI: 1,18-5,23). Sonuç: Bu çalışmanın sonuçları, PSMD9 rs14259 polimorfizminde GG genotipi ve G allelinin Türk DM hastalarında DDPN riskinin artması ile ilişkili olabileceğini göstermektedir.

🔖

Cite This Article

ŞALÇİNİ, C., SÜNTER, G., ÖZEN, F., ÖZER, Y., ARSLAN, B. A. (2021). Proteasome Modulator 9 Gene rs14259 Polymorphism in Patients with Diabetic Polyneuropathy. Nöropsikiyatri Arşivi, Cilt: 58 - Sayı: 4, 289–291. https://ajindex.com/articles/389396

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Edwards KL, Alvarez C, Irons BK, Fields J. Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin. Pharmacotherapy 2008;28:506–521
  2. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956–962
  3. Salcini C, Atasever-Arslan B, Sunter G, Gur H, Isik FB, Saylan CC, Yalcın AD. High Plasma Pentraxin 3 Levels in Diabetic Polyneuropathy Patients with Nociceptive Pain. Tohoku J Exp Med 2016;239:73–79
  4. Russell JW, Zilliox LA. Diabetic neuropathies. Continuum (Minneap Minn) 2014;20:1226–1240.
  5. Zilliox L, Russell JW. Treatment of diabetic sensory polyneuropathy. Curr Treat Options Neurol 2011;13:143–159
  6. Cotton CM, Murray JC. The Human Genome and Neonatal Care. In: Gleason C, Juul S, editors. Avery’s Diseases of the Newborn (10th ed.). Elsevier; 2018. pp.180–189
  7. Hopper LJ, Begum N, Smith L, Hughes AT. The role of PSMD9 in human disease: future clinical and therapeutic implications. AIMS Mol Sci 2015;2:476–484
  8. Thomas MK, Yao KM, Tenser MS, Wong GG, Habener JF. Bridge-1, a novel PDZ-domain coactivator of E2A-mediated regulation of insulin gene transcription. Mol Cell Biol 1999;19:8492–504
  9. Gragnoli C, Cronsell J. PSMD9 gene variants within NIDDM2 may rarely contribute to type 2 diabetes. J Cell Physiol 2007;212:568–571
  10. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285–2293
  11. Basic-Kes V, Zavoreo I, Bosnar-Puretic M, Ivankovic M, Bitunjac M, Govori V, Demarin V. Neuropathic pain. Acta Clin Croat 2009;48:359–365
  12. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farra JT, Galer BS, Haythorntwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524– 1534
  13. Gragnoli C. PSMD9 is linked to type 2 diabetes neuropathy. J Diabetes Complications 2011;25:329–331
  14. Gragnoli C. Proteasome modulator 9 is linked to mi